PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Lymphoma drug duvelisib tested after transplant – trial ends early
Disease control TerminatedThis phase 2 trial tested the drug duvelisib (Copiktra) as a maintenance therapy after an autologous stem cell transplant in 17 people with T-cell lymphoma. The goal was to see if it could safely delay the cancer from coming back. The study was terminated early, so the full resul…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental CAR T-Cell therapy targets tough lymphoma
Disease control TerminatedThis early-phase trial tested a new treatment called AUTO4 for people with a type of T-cell lymphoma that had come back or not responded to prior therapy. AUTO4 is a CAR T-cell therapy designed to recognize and attack cancer cells carrying a specific marker called TRBC1. The stud…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1, PHASE2 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC